Design Therapeutics Q3 net loss widens to $20.3M
Quarter-end cash, cash equivalents and investment securities were $208.608 million; DT-216P2 updates are expected in Q4 2026 and Q1 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Design Therapeutics, Inc. reported financial results for the three and nine months ended September 30, 2026. For the quarter, research and development expenses were $16.926 million versus $14.589 million in 2025, general and administrative expenses were $5.304 million versus $4.722 million, and net loss was $20.288 million versus $16.997 million. Nine-month net loss was $58.089 million, compared with $53.795 million.
Cash, cash equivalents and investment securities were $208.608 million as of September 30, 2026. The Phase 1/2 RESTORE-FA trial of DT-216P2 is ongoing; an update on registrational plans is expected in Q4 2026, with data following 12 weeks of treatment expected in Q1 2027. The Phase 1 multiple-ascending dose trial of DT-818 and Phase 2 biomarker trial of DT-168 are ongoing, with data anticipated in 2027. Design continues preclinical characterization of candidate molecules for Huntington’s disease.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointQuarterly net loss rose to $20.288 million from $16.997 million; nine-month net loss was $58.089 million, compared with $53.795 million.
8-K Event Classification
Key Figures
Key Terms
GeneTAC® technical
multiple ascending dose medical
registrational plans regulatory
corneal endothelium biomarkers medical
mutant DMPK allele medical
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were DSGN's nine-month R&D and G&A expenses in 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 |
Results of Operations and Financial Condition. |
On November 4, 2026, Design Therapeutics, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release of Design Therapeutics, Inc. dated November 4, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Design Therapeutics, Inc. |
|
|
|
|
Date: |
November 4, 2026 |
By: |
/s/ Pratik Shah, Ph.D. |
|
|
|
Pratik Shah, Ph.D. |
Exhibit 99.1
Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027
Cash and securities of $208.6 million at quarter-end provide strong financial runway
Carlsbad, Calif., November 4, 2026 - Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio.
“We remain focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia,” said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. “In DM1, our Phase 1 trial of DT-818 is evaluating an approach designed to selectively reduce transcription of the mutant DMPK allele, targeting the source of toxic RNA. Clinical readouts expected in 2027 will help guide these programs as we pursue our vision for the GeneTAC® platform: to address the underlying causes of serious genetic diseases and deliver meaningful benefits for patients.”
Corporate Highlights
Third Quarter 2026 Financial Results
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the progression or completion of certain development activities; the initiation and progression of studies and clinical trials for DT-216P2, DT-168 and DT-818 and the timing thereof; the anticipated timing for data readouts and other program updates; Design's ability to advance the GeneTAC® platform; Design’s estimated cash runway and the sufficiency of its resources to support its planned operations; and the capabilities and potential advantages of Design’s pipeline of GeneTAC® molecules. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “designed to,” “anticipates,” “capable of,” “plans to,” “expects,” “estimate,” “intends,” “will,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Design’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the data we observe from early clinical and nonclinical studies may impact our clinical development plans; pursuing a biomarker-driven clinical development strategy carries increased risks as there are currently a limited number of approved biomarker-specific therapies; nonclinical development activities and results of nonclinical studies; conducting a clinical trial and patient enrollment and retention, which are affected by many factors, and any difficulties or delays encountered with such clinical trial or patient enrollment or retention may delay or otherwise adversely affect Design’s clinical development plans; the process of discovering and developing therapies that are safe and effective for use as human therapeutics and operating as a development stage company; undesirable side effects or other undesirable properties, which could cause Design or regulatory authorities to suspend or discontinue clinical trials and thereby delay or prevent Design’s product candidates’ development or regulatory approval; Design’s ability to develop, initiate or complete nonclinical studies and clinical trials for its product candidates on the timeframe anticipated, or at all; whether promising early research or clinical trials will result in demonstrated safety and/or efficacy in later clinical trials; changes in Design’s plans to develop its product candidates; reliance on third parties to successfully conduct clinical trials and nonclinical studies; competitive products, which may make any products we develop or seek to develop obsolete or noncompetitive; Design’s reliance on third parties, including contract manufacturers and contract research organizations; interactions with regulatory authorities; Design’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries;
Design’s ability to obtain and maintain intellectual property protection for its product candidates; and Design’s ability to recruit and retain key scientific or management personnel. For a more detailed discussion of these and other factors, please refer to Design’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of Design’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the SEC on August 3, 2026, and under the “Risk Factors” heading of Design’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Design undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
# # #
Contact:
Renee Leck, THRUST
renee@thrustsc.com
DESIGN THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
|
(unaudited) |
|
|||||||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
16,926 |
|
|
$ |
14,589 |
|
|
$ |
47,693 |
|
|
$ |
45,704 |
|
General and administrative |
|
|
5,304 |
|
|
|
4,722 |
|
|
|
16,420 |
|
|
|
15,594 |
|
Total operating expenses |
|
|
22,230 |
|
|
|
19,311 |
|
|
|
64,113 |
|
|
|
61,298 |
|
Loss from operations |
|
|
(22,230 |
) |
|
|
(19,311 |
) |
|
|
(64,113 |
) |
|
|
(61,298 |
) |
Other income, net |
|
|
1,942 |
|
|
|
2,314 |
|
|
|
6,024 |
|
|
|
7,503 |
|
Net loss |
|
$ |
(20,288 |
) |
|
$ |
(16,997 |
) |
|
$ |
(58,089 |
) |
|
$ |
(53,795 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss per share, basic and diluted |
|
$ |
(0.32 |
) |
|
$ |
(0.30 |
) |
|
$ |
(0.93 |
) |
|
$ |
(0.95 |
) |
Weighted-average shares of common stock outstanding, basic and diluted |
|
|
63,035,529 |
|
|
|
56,950,999 |
|
|
|
62,330,974 |
|
|
|
56,856,779 |
|
DESIGN THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
(in thousands)
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash, cash equivalents and investment securities |
|
$ |
208,608 |
|
|
$ |
219,845 |
|
Prepaid expenses and other current assets |
|
|
5,355 |
|
|
|
3,939 |
|
Total current assets |
|
|
213,963 |
|
|
|
223,784 |
|
Property and equipment, net |
|
|
573 |
|
|
|
981 |
|
Right-of-use asset |
|
|
2,272 |
|
|
|
1,438 |
|
Total assets |
|
$ |
216,808 |
|
|
$ |
226,203 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
2,078 |
|
|
$ |
2,312 |
|
Accrued expenses and other current liabilities |
|
|
10,675 |
|
|
|
10,743 |
|
Total current liabilities |
|
|
12,753 |
|
|
|
13,055 |
|
Operating lease liability |
|
|
1,859 |
|
|
|
645 |
|
Total liabilities |
|
|
14,612 |
|
|
|
13,700 |
|
Total stockholders’ equity |
|
|
202,196 |
|
|
|
212,503 |
|
Total liabilities and stockholders’ equity |
|
$ |
216,808 |
|
|
$ |
226,203 |
|